Childhood immunisation in Bungoma County, Kenya, from 2008 to 2011: need for improved uptake

G W Mbuthia1, A D Harries2, A A Obala1

  • 1College of Health Sciences, Moi University, Eldoret, Kenya.

Public Health Action
|October 2, 2015
PubMed

Insights

Childhood immunisation rates in Bungoma County, Kenya, significantly declined between 2008-2011. This drop in vaccine uptake raises concerns for potential outbreaks of preventable diseases.

Area of Science:

  • Public Health
  • Epidemiology
  • Pediatrics

Background:

  • Childhood immunisation is crucial for preventing infectious diseases.
  • Monitoring vaccine uptake is essential for public health surveillance.
  • Declining immunisation rates pose a significant public health risk.

Purpose of the Study:

  • To determine immunisation uptake in children aged 1-2 years in Bungoma County, Kenya.
  • To analyze trends in childhood immunisation coverage over a defined period.
  • To identify potential declines in vaccine uptake and their implications.

Main Methods:

  • Utilized data from 6-monthly Health and Demographic Surveillance System surveys.
  • Assessed 2699 children in Bungoma County between 2008 and 2011.
  • Analyzed trends in full immunisation and specific vaccine uptake (measles, oral polio, pentavalent).

Main Results:

  • Full immunisation coverage significantly decreased from 84% to 58% (P < 0.001).
  • Measles vaccine uptake declined from 89% to 60% (P < 0.001).
  • Significant annual decreases were observed for third doses of oral polio and pentavalent vaccines (P < 0.001).

Conclusions:

  • The study highlights a concerning decline in childhood immunisation in Bungoma County.
  • Low immunisation coverage increases the risk of vaccine-preventable disease outbreaks.
  • Further research is needed to understand the drivers behind these declining immunisation trends.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
53.9K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
783
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
732
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
375